Skip to main content
letter
. 2021 Aug 30;100(5):1132–1135. doi: 10.1016/j.kint.2021.08.017

Figure 1.

Figure 1

(a) Prevalence of anti-spike IgG seroconversion following 1, 2, and 3 mRNA injections in kidney transplant recipients. (b) Antibodies titers (electrochemiluminescence immunoassay by Roche Elecsys) 1 month after the second and third mRNA injections. (c) The evolution of antibody titers in previously positive patients who received a third mRNA injection.